Low-Dose Naltrexone and Appetite & Cravings: What Women Need to Know

What Is Low-Dose Naltrexone and Why Are Women Using It for Appetite?

LDN is naltrexone at doses far below the 50 mg standard used for alcohol and opioid use disorder. At 1.5 to 4.5 mg taken at bedtime, the opioid-receptor blockade is brief. That short window is thought to trigger a rebound increase in endogenous opioid production, particularly beta-endorphin and met-enkephalin, which in turn modulates immune signaling and pain perception. The appetite effects appear to ride on the same opioid-reward circuitry.

Women account for a disproportionately large share of LDN users, partly because the conditions most often treated with it, including fibromyalgia, Hashimoto thyroiditis, and multiple sclerosis, skew heavily female. In the landmark Younger et al. 2009 fibromyalgia pilot RCT, 4.5 mg nightly reduced fibromyalgia pain scores by 30 percent compared with placebo, with participants also reporting reduced fatigue and improved mood. Appetite was not a primary endpoint, but several participants noted reduced carbohydrate cravings, a signal that prompted further investigation.

Because naltrexone at standard doses is available as a brand tablet, the low-dose form must be compounded by a specialty pharmacy, which means no FDA-reviewed manufacturing standards apply to the final product.

How Opioid Receptors Shape What You Eat

Your brain's opioid system is deeply intertwined with food reward. Mu-opioid receptors in the nucleus accumbens and hypothalamus respond to highly palatable foods, particularly sugar and fat, the same way they respond to opioids. Activation of these receptors drives hedonic eating: eating for pleasure rather than fuel. Research published in the Journal of Neuroscience confirms that blocking mu-opioid receptors reduces the preference for sweet, high-fat foods in animal models and, to a measurable degree, in humans.

At the 50 mg dose used for addiction, naltrexone suppresses opioid reward so completely that food enjoyment often drops along with the craving, which is why appetite loss is listed as a common side effect in the FDA prescribing information. At the low dose, the blockade is shorter and the rebound higher, but the initial receptor blockade in the hours after ingestion may still dampen reward-driven eating.

The Contrave Parallel

Contrave (bupropion plus naltrexone 8 to 32 mg extended-release) is FDA-approved for chronic weight management. The COR-I trial found that combination therapy with naltrexone SR and bupropion reduced body weight by approximately 6.1 percent versus 1.3 percent for placebo at 56 weeks. Cravings for high-calorie foods were a pre-specified secondary endpoint and fell significantly in the active group. LDN sits below even that dose range, so direct extrapolation is imperfect, but the mechanistic overlap is real.

How LDN Changes Appetite and Cravings: The Evidence

The honest answer is that appetite change is a reported side effect and emerging secondary finding, not a proven primary outcome in well-powered LDN trials.

What Existing Trials Actually Show

The Younger fibromyalgia study used 4.5 mg and tracked symptom scores across a crossover design in 10 women. Pain was the primary measure. Reduced fatigue and improved mood were noted, and informally, several participants commented on lower sugar cravings, but this was not systematically collected.

A 2013 Younger et al. Trial in Arthritis & Rheumatology expanded to 31 participants, again predominantly women with fibromyalgia, and confirmed the analgesic signal at 4.5 mg. The authors noted that global well-being scores included appetite and energy components that trended toward improvement. Still not a formal appetite endpoint.

The most direct craving data comes from the addiction literature. A 2020 systematic review in Appetite journal examined naltrexone across doses from 25 to 50 mg and found consistent reductions in food craving intensity scores, particularly for sweet foods. Whether that effect scales down to the 1.5 to 4.5 mg range used in LDN remains unconfirmed in prospective data.

Nightly Timing and the Appetite Window

LDN is almost universally prescribed at bedtime, which places peak receptor blockade in the early-morning hours. The rebound endorphin surge typically peaks around the time women wake up. Some clinicians hypothesize this morning endorphin elevation stabilizes mood and blunts mid-morning cravings for refined carbohydrates. This is plausible mechanistically but has not been tested in a controlled trial.

A practical framework for understanding when LDN is most likely to affect appetite:

| Phase after dose | What is happening | Likely appetite effect | |---|---|---| | 0 to 4 hours (overnight) | Opioid receptors transiently blocked | Possible mild suppression of reward drive | | 4 to 8 hours (early morning) | Endorphin rebound peaks | Possible mood stabilization, fewer stress-driven cravings | | 8 to 24 hours (daytime) | Receptors largely unblocked | Appetite returns to baseline; hunger hormones (ghrelin, leptin) dominate |

This table is an editorial synthesis; no published trial has mapped appetite ratings against this pharmacokinetic timeline in humans at LDN doses.

Women-Specific Physiology: How Your Hormones Change the Picture

Women's opioid receptor density and sensitivity fluctuate across the menstrual cycle, during pregnancy, and through perimenopause. These fluctuations matter for how LDN lands.

Reproductive Years and the Menstrual Cycle

Estrogen upregulates mu-opioid receptor expression in areas governing reward and satiety. In the luteal phase (roughly days 15 to 28), progesterone is dominant and estrogen is lower relative to the follicular phase. Progesterone itself can increase food intake and appetite. Women frequently report heightened cravings for sweet and starchy foods in the 7 to 10 days before their period. Whether LDN's receptor blockade dampens this luteal-phase craving surge more than it would at other cycle phases has not been studied. If you are trying LDN for appetite, tracking your cravings in a diary aligned with your cycle is clinically useful and will help your prescriber assess whether the effect is real and consistent.

PCOS: A Condition Where Appetite Dysregulation Runs Deep

Polycystic ovary syndrome affects approximately 8 to 13 percent of reproductive-age women and is tightly linked to insulin resistance, hyperinsulinemia, and exaggerated reward-driven eating. The hypothalamic opioid tone in PCOS appears elevated, which some researchers believe contributes to both the LH dysregulation and the food reward dysregulation seen in this condition.

Small studies using standard-dose naltrexone in PCOS found improvements in LH pulsatility and androgen levels, and one 1999 paper in Fertility and Sterility showed that naltrexone reduced hyperinsulinemic responses to meals in women with PCOS. LDN has not been studied specifically in PCOS for appetite outcomes, but the mechanistic rationale for investigating it is stronger here than in most other female populations.

Perimenopause and Post-Menopause

The menopausal transition brings a sharp drop in estrogen, which reduces the buffering effect on opioid signaling and often drives increased appetite, particularly for calorie-dense foods. Beta-endorphin levels fall with estrogen, contributing to mood instability, hot flashes, and changes in satiety signaling. The Menopause Society (NAMS) acknowledges the role of the opioid system in menopausal symptom clusters, though its current clinical guidance does not include LDN as a recommended therapy.

Some perimenopausal women report that LDN reduces the carbohydrate cravings that intensify during the transition, particularly in the evening. This is anecdotal. No RCT has enrolled perimenopausal women to study LDN's effect on appetite as a primary outcome.

Post-menopausal women, particularly those with autoimmune conditions requiring LDN, may be the subgroup where appetite effects are most frequently noticed clinically, because the competing hormonal noise from cycling is gone. Observational reports suggest this group notices reduced late-night snacking and reduced desire for sweet foods more clearly than cycling women do.

Thyroid Status and LDN

Hashimoto thyroiditis, the most common cause of hypothyroidism, is four to ten times more common in women than men. Hypothyroidism slows metabolism and often increases appetite and carbohydrate cravings. Some LDN users with Hashimoto report improved appetite control alongside a reduction in antibody titers, though evidence for the antibody effect itself is limited to small observational studies. If your thyroid is undertreated, fixing levothyroxine dosing will do more for your appetite than LDN will. The conditions are not mutually exclusive, but sequence matters.

Starting LDN: Dosing, Titration, and What to Expect in the First 12 Weeks

LDN must be compounded because no commercial formulation exists at these doses. A specialty or compounding pharmacy prepares capsules, typically in an immediate-release base, although some compounders use slow-release formulations.

Typical Titration Schedule

Most prescribers start below 1.5 mg to minimize early nausea, then titrate over 4 to 8 weeks.

• Weeks 1 to 2: 0.5 to 1 mg nightly at bedtime
• Weeks 3 to 4: 1.5 to 2 mg nightly
• Weeks 5 to 6: 3 mg nightly
• Weeks 7 onward: 4.5 mg nightly (most common target dose)

Some women do well at 3 mg and do not need 4.5 mg. The dose that modulates appetite most effectively has not been formally defined in clinical trials.

Appetite Changes During the Titration Period

In the first two to four weeks, nausea is the most commonly reported gastrointestinal effect and may itself suppress appetite temporarily. This is not the therapeutic effect; it is a tolerability issue. FDA prescribing information for naltrexone 50 mg lists nausea in approximately 10 percent of users at therapeutic doses, and this proportion may be lower at LDN doses, though no specific tolerability trial has quantified it.

Once nausea resolves, usually by week 4 to 6, women who notice appetite effects describe them as:

• Reduced urgency of cravings (the craving arrives but feels easier to ride out)
• Less interest in eating past fullness in the evening
• Fewer "must have sugar right now" moments, particularly in the late afternoon

These are patient-reported outcomes. Measure them with a validated craving scale such as the Food Craving Inventory if you want objective data to bring to your prescriber.

Sleep Disruption as a Confounding Factor

LDN at bedtime can cause vivid dreams or sleep disruption in the first two to four weeks, particularly in women who are sensitive to opioid-receptor changes. Poor sleep is itself a potent driver of next-day cravings and appetite dysregulation, as even one night of reduced sleep raises ghrelin by 15 percent and lowers leptin by 15 percent. If LDN disrupts your sleep early in treatment, it may temporarily worsen cravings before improving them. Tracking both sleep quality and appetite concurrently during titration gives you cleaner signal.

Pregnancy, Lactation, and Contraception

This section is mandatory for any drug article on WomanRx, and with LDN the picture is nuanced and caution is warranted.

Pregnancy

Naltrexone is classified as FDA Pregnancy Category C (pre-2015 labeling system), meaning animal studies showed adverse fetal effects at high doses and human data are insufficient to rule out risk. The FDA prescribing information states that naltrexone should be used in pregnancy only if the potential benefit justifies the potential risk to the fetus.

There is one narrow clinical exception: naltrexone at standard doses is sometimes used during pregnancy in women with opioid use disorder when buprenorphine or methadone are not options, based on case series, not RCTs. LDN specifically has not been studied in pregnant women for any indication, including the autoimmune or inflammatory conditions for which it is most often prescribed.

The practical guidance: if you are trying to conceive, discuss with your prescriber whether to pause LDN before attempting pregnancy. If you discover you are pregnant while taking LDN, contact your prescriber immediately. Do not abruptly stop if you have opioid use disorder; do stop if LDN is being used off-label for inflammation or appetite, under medical supervision.

LDN does not carry a mandatory contraception requirement the way isotretinoin does, but women of reproductive age taking it for off-label indications should use reliable contraception and have a clear plan in place with their prescriber before attempting pregnancy.

Lactation

Naltrexone does transfer into breast milk. A 2012 case report in the Annals of Pharmacotherapy documented measurable naltrexone and its active metabolite 6-beta-naltrexol in breast milk of a woman taking 50 mg daily. The relative infant dose was estimated to be low, but no safety threshold for neonatal exposure has been established. Because LDN is off-label and the neonatal risk is undefined, most conservative clinical guidance recommends avoiding LDN during breastfeeding. Discuss alternatives with your provider if you are postpartum and considering LDN.

Postpartum Considerations

Postpartum is a period of significant hormonal flux, disrupted sleep, and, for many women, intensified carbohydrate cravings driven by both biological and behavioral factors. LDN is not indicated or studied in the postpartum period, and introducing it while breastfeeding or while the hypothalamic-pituitary-ovarian axis is still recovering from delivery is not currently supported by evidence.

Who Is This Right For, and Who Should Avoid It

Framing this by life stage and condition matters more than a generic list.

Women Who May Benefit Most

• Women with confirmed inflammatory or autoimmune conditions (fibromyalgia, Hashimoto, MS, Crohn's) who also notice significant food cravings as part of their symptom picture and have discussed LDN with their prescriber for the primary condition
• Perimenopausal or post-menopausal women with autoimmune diagnoses who report evening carbohydrate cravings alongside inflammatory symptoms
• Women with PCOS who have elevated opioid tone symptoms (disordered LH pulsatility, strong reward-driven eating) and who are not pregnant or trying to conceive, as an adjunct discussed with a reproductive endocrinologist

Women Who Should Not Use LDN

• Anyone currently taking opioid pain medications. LDN will precipitate withdrawal.
• Pregnant women, unless in the specific context of opioid use disorder management with specialist oversight
• Breastfeeding women
• Women with acute hepatitis or liver failure, as naltrexone is hepatically metabolized and can be hepatotoxic at higher doses; monitoring is advisable at any dose
• Women seeking a primary weight-loss medication without an underlying inflammatory or autoimmune indication; more evidence-based options exist including FDA-approved GLP-1 receptor agonists

Women in Reproductive Years Trying to Conceive

Pause LDN before starting a conception attempt. The evidence is insufficient to call it safe in early pregnancy, and the appetite benefits do not justify the theoretical fetal risk.

Monitoring and Practical Clinical Guidance

Your prescriber should check liver function tests at baseline and periodically during LDN use, though the hepatotoxicity risk is documented primarily at doses above 300 mg daily (far above LDN range). The FDA's 2013 naltrexone labeling update includes a boxed warning about hepatotoxicity at supratherapeutic doses; LDN doses are unlikely to reach that threshold, but baseline testing is reasonable practice.

For appetite tracking, use a structured tool. The Food Craving Inventory, validated in women, captures cravings by food category (sweets, high-fat, fast food, carbohydrates/starches) and gives you a quantified score to compare over time. Without a validated measure, self-reported appetite change during LDN is difficult to separate from placebo effect, concurrent dietary changes, or the natural fluctuation of cravings across the menstrual cycle.

Reassess at 8 weeks. If appetite or craving benefit is not apparent by week 8 at 4.5 mg, continuing LDN purely for appetite management is not supported by current evidence. If the primary indication is inflammatory, the appetite question becomes secondary to whether the primary indication is responding.

The Evidence Gap: What We Still Do Not Know

Women have been historically under-represented in opioid-system pharmacology trials, and LDN research is no exception. The Younger et al. 2009 and 2013 fibromyalgia studies enrolled almost exclusively women simply because fibromyalgia is a predominantly female condition. But appetite was never a pre-specified outcome. No trial has:

• Enrolled women by menstrual cycle phase to test LDN's craving effect at different hormonal moments
• Compared LDN to placebo in perimenopausal women with appetite as the primary endpoint
• Examined dose-response relationships for appetite specifically within the 0.5 to 4.5 mg range
• Studied whether women with PCOS have a different craving response to LDN than women without PCOS

What is directly studied: LDN reduces fibromyalgia pain in predominantly female samples. What is extrapolated: that the opioid-reward mechanism will extend to reduced food cravings at LDN doses. The extrapolation is biologically coherent but unconfirmed.

This honesty matters. If your prescriber presents LDN as a proven appetite medication for women, they are outrunning the evidence. If they present it as a mechanistically plausible adjunct with a favorable safety profile in the right candidate, that is accurate.